Sahajanand Medical Technologies Limited (SMT), a Gujarat-based manufacturer of advanced cardiovascular medical devices, is preparing to launch its initial public offering on October 15, 2026. The company specialises in products used in vascular and structural heart interventions, including coronary stents, angioplasty balloons and transcatheter heart valves.
The IPO has a price band of ₹327–₹344 per share and an issue size of approximately ₹475.48 crore. The subscription period will run from October 15 to October 19, 2026, with the proposed listing on BSE and NSE on October 23, 2026.
The offering is entirely an Offer for Sale (OFS), meaning the company will not receive fresh capital from the IPO. Instead, existing shareholders will sell a portion of their holdings to public investors.
Sahajanand Medical Technologies IPO Details
| IPO Details | Information |
|---|---|
| Company Name | Sahajanand Medical Technologies Limited |
| IPO Type | Mainboard IPO |
| Issue Type | Book Built, OFS Only |
| IPO Open Date | October 15, 2026 |
| IPO Close Date | October 19, 2026 |
| Price Band | ₹327–₹344 |
| Face Value | ₹1 per share |
| Total Issue Size | ₹475.48 crore |
| Fresh Issue | Nil |
| Offer for Sale | 1,38,22,116 shares |
| Lot Size | 43 shares |
| Minimum Investment | ₹14,792 |
| Anchor Investor Date | October 14, 2026 |
| Basis of Allotment | October 21, 2026 (tentative) |
| Refund Initiation | October 22, 2026 |
| Demat Credit | October 22, 2026 |
| Expected Listing Date | October 23, 2026 |
| Listing Exchanges | BSE and NSE |
| Lead Managers | Motilal Oswal, Avendus Capital, HSBC Securities, Nuvama Wealth Management |
| Registrar | MUFG Intime India |
The IPO includes a reservation of 2.5 lakh shares for eligible employees. Of the remaining net offer, up to 50% is allocated to qualified institutional buyers, at least 15% to non-institutional investors and at least 35% to retail investors. At the upper price band, the company’s implied market capitalisation is approximately ₹3,497 crore.
Also Read: Tonbo Imaging India IPO Details: Price Band, Dates, Financials, GMP and Business Model
The issue terms and financial figures have been cross-checked against the October 2026 IPO announcements and prospectus-based reporting.
Moneycontrol
+2
Business Model and Product Portfolio
Sahajanand Medical Technologies is a research-and-development-driven medical device company operating in the cardiovascular healthcare industry. Its business focuses on designing, developing, manufacturing and commercialising medical devices used by healthcare professionals during procedures involving blood vessels and structural heart conditions.
Also Read: Zetwerk Manufacturing Business IPO Details: Price Band, Dates, Financials, GMP and Business Model
The company participates in a specialised market where product performance, clinical evidence, manufacturing precision and regulatory approvals are essential. Unlike general medical consumables manufacturers, SMT develops high-risk implantable and interventional devices that require extensive testing and ongoing quality controls.
Its vascular intervention portfolio includes coronary stents and balloons used during procedures intended to restore blood flow through narrowed or blocked arteries. The company also manufactures peripheral vascular products and renal stents, allowing it to address applications beyond coronary interventions.
In structural heart interventions, SMT develops devices including transcatheter aortic valve implantation (TAVI) systems and occluders. These products are associated with specialised cardiac procedures and require sophisticated engineering, material science and clinical validation.
The company operates in both domestic and international markets, with its products supplied through healthcare distribution networks and medical institutions.
Also Read: Bonfiglioli Transmissions IPO Details
Research, Technology and Innovation
Research and development form an important part of SMT’s business strategy. Cardiovascular medical devices require continuous innovation because manufacturers must improve device deliverability, durability, compatibility and procedural performance while meeting demanding clinical and regulatory requirements.
The company’s product development activities include drug-eluting coronary stents, balloon technologies and structural heart devices. Clinical research and published studies support the evaluation of certain products, although evidence for one device should not automatically be applied to the company’s entire portfolio.
Its Supraflex family of coronary stents and Hydra transcatheter heart valve technology are examples of its cardiovascular product development activities. The company has participated in clinical investigations involving these technologies, reflecting the importance of scientific evidence in the medical device industry.
The ability to develop proprietary technology can help manufacturers differentiate their products. However, commercial success also depends on regulatory clearances, physician adoption, hospital procurement, manufacturing quality and competition from established international companies.
Also Read: Fusion CX IPO Details: Price Band, Dates, Financials and Key Risks
Global Presence and Market Reach
Sahajanand Medical Technologies has established a substantial international presence. During FY2026, its business extended across 77 countries, including India. For the quarter ended June 30, 2026, the company reported a presence in 65 countries.
This geographical reach allows SMT to participate in international cardiovascular device markets rather than depending exclusively on domestic hospital demand. It also creates opportunities to expand distribution relationships and introduce additional products in markets where the company has obtained the necessary regulatory permissions.
However, international medical device markets have different regulatory frameworks, procurement systems and reimbursement arrangements. Obtaining permission to market a device in one country does not automatically permit its sale in another. Consequently, regulatory compliance and ongoing product quality remain central to SMT’s international growth strategy.
Sahajanand Medical Technologies Financial Performance
Sahajanand Medical Technologies reported growth in revenue and profitability during FY2026, with profit increasing substantially faster than sales.
Also Read: HD Fire Protect IPO Details
| Financial Metric | FY2025 | FY2026 |
|---|---|---|
| Revenue from Operations | ₹1,024.88 crore | ₹1,210.50 crore |
| EBITDA | ₹128.02 crore | ₹170.65 crore |
| Profit After Tax | ₹25.15 crore | ₹69.08 crore |
Revenue from operations increased approximately 18.1% in FY2026, while profit after tax increased approximately 174.6%. EBITDA also improved, reflecting stronger operating earnings during the period.
For the quarter ended June 30, 2026, the company reported revenue from operations of ₹351.67 crore, EBITDA of ₹48.58 crore and profit after tax of ₹15.09 crore.
The improvement in annual profitability is notable, but investors should evaluate the underlying drivers, including product mix, operating expenses, finance costs and other income, before assuming that the same growth rate will continue. Medical device businesses can also experience changes in margins because of research expenditure, international expansion, regulatory costs and pricing pressures.
IPO Structure and Use of Proceeds
The Sahajanand Medical Technologies IPO consists entirely of an Offer for Sale of up to 1,38,22,116 equity shares. Selling shareholders include Shree Hari Trust, Dhirajkumar Savjibhai Vasoya, Samara Capital Markets Holding, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding B.V.
Also Read: Vishal Nirmiti IPO Details
Because there is no fresh issue component, the company will not receive proceeds from the public offering. The money raised through the share sale will go to the selling shareholders, after applicable offer-related expenses.
This distinction is important when evaluating the IPO. Listing may provide greater liquidity, visibility and access to public capital markets in the future, but the present offering does not directly finance new manufacturing facilities, research programmes, debt repayment or working-capital expansion.
Growth Opportunities
The cardiovascular medical device industry presents opportunities associated with the treatment of coronary artery disease, peripheral vascular conditions and structural heart disorders. Demand is influenced by healthcare infrastructure, clinical adoption of interventional procedures, patient access and medical technology development.
SMT’s portfolio spans established coronary intervention products and more specialised structural heart technologies. This combination provides exposure to different categories of cardiovascular procedures, although each category has its own clinical, commercial and regulatory requirements.
Also Read: Nityas Gems & Jewellery IPO Details
International expansion could also support growth as the company broadens distribution and product registrations. Its existing presence across multiple countries provides a foundation, but expanding sales requires continuing investment in regulatory compliance, physician education, clinical evidence and customer relationships.
Research and development remain another important opportunity. Developing new products and improving existing technologies could help SMT compete in specialised segments where clinical performance and product reliability influence purchasing decisions.
Key Risks
One of the company’s principal risks is the highly regulated nature of medical device manufacturing. Products used in cardiovascular interventions must meet demanding safety, quality and performance requirements. Regulatory delays, product recalls, manufacturing defects or adverse clinical findings could affect operations, reputation and financial performance.
Competition is another major consideration. SMT competes in a market that includes established multinational medical technology companies and specialised regional manufacturers. Competitors may have larger research budgets, stronger distribution networks and extensive clinical evidence supporting their products.
Also Read: SRIT India IPO Details
The business also depends on successful research and product development. New devices may require substantial investment before commercialisation, and clinical or regulatory outcomes may not meet expectations. Even after approval, adoption depends on healthcare professionals, hospitals, distributors and pricing conditions.
International operations expose the company to currency fluctuations, changing regulations, trade restrictions and different healthcare reimbursement systems. These factors can influence demand and profitability across markets.
Finally, the IPO is entirely an OFS. Although the company has reported improving financial performance, the offering will not provide additional capital for its future expansion.
Sahajanand Medical Technologies IPO GMP
The grey market premium, or GMP, is an unofficial indication of market sentiment ahead of an IPO listing. It is not determined by the company or stock exchanges and can change substantially during the subscription period.
Also Read: Shah Investor’s Home IPO Details
A sufficiently reliable, current GMP quotation could not be established for this article as of October 13, 2026. Therefore, no numerical premium or implied listing price is being reported.
Investors should distinguish unofficial grey-market activity from the company’s financial performance, offer valuation and formal subscription data.
Financial Disclaimer: This article is published by Onetrader.in for educational and informational purposes only. It does not constitute investment advice, a recommendation to subscribe to or avoid an IPO, or a guarantee of listing gains or future returns. Onetrader is not a SEBI-registered investment adviser or research analyst. Investors should review the company’s Red Herring Prospectus, assess the associated risks and consult a qualified financial professional before making investment decisions.
Also Read: AceVector IPO Details: Price Band, Dates, Financials, GMP and Key Risks
Keep learning with OneTrader
Explore structured lessons and practical guides to build your market knowledge.